The most common forms of acquired epilepsies arise following acute brain insults such as
traumatic brain injury, stroke, or central nervous system infections. Treatment is effective for …

From an evolutionary perspective keratan sulfate (KS) is the newest glycosaminoglycan
(GAG) but the least understood. KS is a sophisticated molecule with a diverse structure, and …

Here, we show that the synaptic vesicle protein SV2A is the brain binding site of
levetiracetam (LEV), a new antiepileptic drug with a unique activity profile in animal models …

Diverse brain insults, including traumatic brain injury, stroke, infections, tumors,
neurodegenerative diseases, and prolonged acute symptomatic seizures, such as complex …

Originally described as a model of 'psychomotor seizures'(J. Pharmacol. Exp. Ther.(1953)
107–273), the 6 Hz corneal stimulation model was abandoned shortly after its description …

A variety of acute brain insults can induce epileptogenesis, a complex process that results in
acquired epilepsy. Despite advances in understanding mechanisms of epileptogenesis …

Control of epilepsy has primarily focused on suppressing seizure activity by antiepileptic
drugs (AEDs) after epilepsy has developed. AEDs have greatly improved the lives of people …

Post-stroke epilepsy (PSE) is a common complication after stroke, yet treatment options
remain limited. While many physicians prescribe antiepileptic drugs (AED) for secondary …

Better information of the natural history of epilepsy has important implications for
understanding the underlying neurobiology, evaluating treatment strategies, and planning …

Levetiracetam is a novel orally active antiepileptic drug with a unique preclinical profile. It
has a high therapeutic index and potential antiepileptogenic effects. Results of clinical trials …